{"entity":{"id":"nct06532812","kind":"trial","name":"TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer","aka":["BAH249"],"tldr":"A phase 1/2 trial of fludarabine, aldesleukin (high-dose il-2) and pembrolizumab in triple-negative breast cancer, run by Essen Biotech, now recruiting.","summary":"TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer is a phase 1/2, interventional study registered as NCT06532812 by Essen Biotech, with a registry enrolment figure of 85 participants, started 2024-08-22 and due to reach its primary completion in 2025-12-10. Interventions recorded: Tumor Infiltrating Lymphocytes (TIL); Cyclophosphamid; Fludarabine; Interleukin-2; Pembrolizumab. Conditions listed: Breast Cancer; Breast Carcinoma; Breast Cancer Metastatic; Breast Cancer Triple Negative. Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06532812","url":"https://clinicaltrials.gov/study/NCT06532812"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["fludarabine","aldesleukin","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06532812","phase":"1/2","setting":"Efficacy and Safety of Autologous Tumor-Infiltrating Lymphocytes (TIL) Therapy Combined With Pembrolizumab (Keytruda) Immunotherapy in Patients With Advanced or Metastatic Refractory Breast Cancer","sponsor":"Essen Biotech","enrolled":85,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06532812/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}